# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Andreas Argyrides initiates coverage on Liquidia (NASDAQ:LQDA) with a Perform rating.
The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Dru...
Needham analyst Serge Belanger reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $28 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $32 price target.